Diagnostic yield of screening colonoscopy in Hodgkin lymphoma survivors.

KI-AV0 个研究点目标入组 259 人开始时间: 待定最近更新: 2024年2月28日

适应症

试验速览

暂无简介。

•HL diagnosis at the age of 16-50 years
•-Treatment for HL between 1965 and 2007
•-Treatment of primary or recurrent HL consisting of infradiaphragmatic radiotherapy and chemotherapy (any regimen) or chemotherapy containing a cumulative procarbazine dose of ≥2.8 g/m2 (e.g. ≥2 MOPP, ≥4 BEACOPP or ≥4 MOPP/ABV courses)
•-Survival of at least 8 years after the first treatment that included infradiaphragmatic radiotherapy and chemotherapy or procarbazine-containing chemotherapy
•-Age of 25 years or older
•-Life expectancy of five years or more
•Inclusion NEW: 4-apr-2016
•-HL diagnosis at the age of 16-50 years

•-Proctocolectomy
•-Colonoscopy surveillance for other indications (including hereditary CRC syndrome, familial CRC syndrome, inflammatory bowel disease, history of colorectal adenoma or CRC)
•-Colonoscopy in the past five years
•-On-going cytotoxic treatment or radiotherapy for malignant disease
•-Coagulopathy (prothrombin time < 50% of control; partial thromboplastin time > 50 seconds) or anticoagulants (marcoumar, acenocoumarol or new oral anticoagulants) that cannot be stopped
•-Comorbidity leading to an impaired physical performance (World health organization (WHO) performance status 3-4) or mental retardation

发起方

KI-AV